Reported 1 day ago
Alnylam Pharmaceuticals, Inc. has received approval from the European Commission for AMVUTTRA, a treatment for transthyretin amyloidosis (ATTR). This follows the FDA's approval in March 2025, reinforcing the drug's efficacy in reducing cardiovascular events in ATTR patients. Alongside its existing treatments for rare diseases, Alnylam is expanding its pipeline with new therapies for conditions such as Huntington's disease and type 2 diabetes, while advancing new RNA interference treatments aimed at long-lasting and convenient patient care.
Source: YAHOO